Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Sanaz Gabery, PhD

Sanaz Gabery defended her doctoral thesis in TNU in 2015, was employed at Novo Nordisk A/S in Denmark and returned to Lund University in 2018. Since 2017 she is combining her research with medical studies at Lund University. Gabery’s current project aims to determine the role of white matter pathology for the development and treatment of Huntington’s disease. Recent studies performed by Gabery and Petersén’s research group have indicated that changes in white matter occur in an early stage of HD, and precede changes in grey matter.


2019 - ongoing: Post doctoral fellow - Hjärnfonden (Brain Foundation) stipendee

2018: Research scientist, TNU, Medical Faculty, Lund University, Sweden

2016 - 2017: Novo Nordisk, Denmark.

2015: Assistant researcher, TNU, Medical Faculty, Lund University, Sweden


2017 - ongoing: Medical programme, Medical Faculty, Lund University, Sweden

2011 - 2015: PhD studies in Neuroscience, Medical Faculty, Lund University, Sweden.
Thesis: New perspectives on pathology in Huntington's disease - characterization of hypothalamic changes.
Supervisor: Associate Professor Åsa Petersén MD PhD, TNU.
2010: Master of Medical Science in biomedicine, major in experimental medicine, Lund university, Lund.
Thesis: Investigation of neuropathological changes in the hypothalamus and forebrain in Huntington’s disease. 
Supervisor: Åsa Petersén MD PhD, Translational Neuroendocrine Research Unit (TNU).

2008: Bachelor in Medical Science, major: Biomedicine, Lund university, Lund.
Thesis: Role of different brain regions in Huntington’s disease - initial studies using adenoassociated viral vector expression of GFP and heterozygote HAP1 mice. 
Supervisor: Åsa Petersén MD PhD, Translational Neuroendocrine Research Unit (TNU).
2004: High school diploma , major: natural science, Malmö Borgarskola, Malmö.


Fjalldal S, Follin C, Gabery S, Sundgren PC, Björkman-Burtscher IM, Lätt J, Mannfolk P, Nordström CH, Rylander L, Ekman B, Cheong R, Pålsson A, Petersén Å and Erfurth EM.
Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity.
International Journal of Obesity (Lond). 2018 Sep 4. doi: 10.1038/s41366-018-0185-z. [Epub ahead of print]

Baldo B, Gabery S, Soylu-Kucharz R, Cheong RY, Henningsen JB, Englund E, McLean C, Kirik D, Halliday G and Petersén Å.
SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease.
Neuropathology and Applied Neurobiology. 2018 Jul 18. doi: 10.1111/nan.12514. [Epub ahead of print]

Fjalldal S, Follin C, Svärd D, Rylander L, Gabery S, Petersen Å, Van Westen D, Sundgren P, Bjorkman-Burtscher I, Lätt J, Ekman B, Johanson A and Erfurth EM.
Microstructural white matter alterations and hippocampal volumes are associated with cognitive deficits in craniopharyngioma.
European Journal of Endocrinology 178 (6): 577-587 (2018)

Follin C, Fjalldal S, Svärd D, van Westen D, Gabery S, Petersén Å, Lätt J, Rylander L and Erfurth EM.
Microstructure alterations in the Hypothalamus in cranially radiated Childhood Leukemia survivors but not in Craniopharyngioma patients unaffected by hypothalamic damage. 
Clinical Endocrinology. 87(4): 359-366 (2017)

Rochel B, Domínguez D J F, Stout J, Gabery S, Churchyard A, Chua P, Egan G, Petersén A, Georgiou-Karistianis N and Poudel G R.
Subjective sleep problems in Huntington's disease: A pilot investigation of the relationship to brain structure, neurocognitive, and neuropsychiatric function.
Journal of the Neurological Sciences 364: 148-153 (2016)

Follin C, Gabery S, Petersén Å, Sundgren PC, Björkman-Burtcher I, Lätt J, Mannfolk P and Erfurth EM.
Associations between Metabolic Risk Factors and the Hypothalamic Volume in Childhood Leukemia Survivors Treated with Cranial Radiotherapy.
PLoS One. Jan 29;11(1):e0147575 (2016)

Gabery S, Georgiou-Karistianis N, Lundh SH, Cheong RY, Churchyard A, Chua P, Stout JC, Egan GF, Kirik D and Petersén Å.
Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study.
PLoS One 10(2) (2015)

Gabery S, Halliday G, Kirik D, Englund E, Petersén Å.
Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study.
Neuropathol Appl Neurobiol. 41(6): 843-848 (2015)

Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D and Petersén Å.
Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
European Journal of Neuroscience 36(6):2789-800 (2012)

Petersen Å and Gabery S.
Hypothalamic and limbic system changes in Huntington's disease.
Journal of Huntington's disease 1: 13-24 (2012)

Piguet O, Petersén A, Yin Ka Lam B, Gabery S, Murphy K, Hodges JR and Halliday GM. 
Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. 
Annals of Neurology 69: 312-319 (2011) 

Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G and Petersén Å.
Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. 
Acta Neuropathologica 120: 777-788 (2010)

Page Manager:

Sanaz Gabery

Sanaz Gabery, Post doc
Born in 1985
Phone: +46 46 222 45 25
E-mail: Sanaz [dot] Rasoly_Gabery [at] med [dot] lu [dot] se (subject: Mail%20from%20TNU%20website)

Lund University
Translational Neuroendocrinology Research Unit
Baravägen 27
221 84 Lund

Translational Neuroendocrine Research Unit
Baravägen 27, BMC D11
221 84 Lund